Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring of ESR1, PIK3CA and AKT ctDNA Mutations During Real-life Followup of Patients With Metastatic Breast Cancer Treated With Aromatase Inhibitors

NCT03318263 is registered in ClinicalTrials.gov with Institut de Cancérologie de Lorraine as lead sponsor.

NCT NCT03318263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03318263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring of ESR1, PIK3CA and AKT ctDNA Mutations During Real-life Followup of Patients With Metastatic Breast Cancer Treated With Aromatase Inhibitors
Lead sponsor
Institut de Cancérologie de Lorraine
Phase
Not applicable
Overall status
Completed
Start date
December 7, 2017
Completion date
December 22, 2022
Enrollment
146 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer